The list of fastest-growing online retailers in North America contains some familiar names in 2025.
In the top 10, each falls into one of two merchant types — Consumer Brand Manufacturers and Retail Chains. However, this cohort also showcases a mix of the continent’s most established names in retail. Those include Mass Merchants such as Walmart and El Puerto de Liverpool, alongside notable rising stars in individual merchandise categories.
Digital Commerce 360’s 2025 Top 1000 Report includes data about all of these merchants. In addition, the report shows which companies saw the largest increases in web sales year over year in 2024. At the top of the list is a Consumer Brand Manufacturer that has made major inroads in the Health & Beauty category over the past decade. Its online sales grew 70.7% year over year. Meanwhile, the company reported even higher overall results for its fiscal first quarter that ended March 31.
That No. 1 ranking for fastest-growing retailers overall, as well as in the Health & Beauty category, belongs to Hims & Hers. Alongside fellow Consumer Brand Manufacturers Vuori and Oddity on the list, Hims & Hers entered 2025 on a strong note. However, the company faced a major challenge over the past week with the termination of a major collaboration.
Who leads the fastest-growing online retailers in North America?
Him & Hers was founded in 2017 and built its brand through telehealth, branching into hair regrowth, sexual health and weight loss. In its Q1 earnings results, the company reported 115.2% online sales growth year over year, which reached $576.4 million during that period.
2025 fastest growing online retailers in the Top 1000 | Image credit: Digital Commerce 360
“Over 80% of subscribers in our dermatology specialty are benefiting from a personalized solution as of the end of the first quarter, which was a critical part in driving nearly 50% year-over-year subscriber growth across those specialties,” said Andrew Dudum, the co-founder and CEO at Hims & Hers, during a call with investors. “Sexual health is following a similar path.”
Him & Hers ranks No. 69 overall in the Top 1000 Database. Digital Commerce 360 projects its online sales will reach $1.94 billion in 2025.
Hims & Hers web sales by year
What Hims & Hers will do following Novo Nordisk dispute
Still, less than one month after its May earnings call, Hims & Hers reached a crossroads in its latest weight loss push. During the call, Dudum stated that within “just 18 months,” weight loss had “become one of our largest specialties.” He mentioned the achievement alongside Hims & Hers’ collaboration with the pharmaceutical company Novo Nordisk. The latter company announced on June 23 that it would terminate that collaboration.
The problem centered around the two companies’ agreement to make Novo Nordisk’s weight loss drug Wegovy available through Hims & Hers. Specifically, Novo Nordisk took issue with Hims & Hers continuing to sell compounded semaglutide, which is the active ingredient in the pharmaceutical giant’s Wegovy and Ozempic drugs.
“When patients are prescribed semaglutide treatments by their licensed health care professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy,” said Dave Moore, executive vice president for U.S. operations at Novo Nordisk. “We will work with telehealth companies to provide direct access to Wegovy that share our commitment to patient safety — and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action.”
In response, Dudum released a public statement on the same day, defending Hims & Hers.
“In recent weeks, Novo Nordisk’s commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients,” Dudum stated. “We refuse to be strong-armed by any pharmaceutical company’s anticompetitive demands that infringe on the independent decision making of providers and limit patient choice.”
According to Dudum, Him & Hers, “will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients.”
📧 Editor’s note: Subscribe to our retail newsletter to make sure you see each weekly edition of Ecommerce Trends.
Do you rank in our databases?
Submit your data and we’ll see where you fit in our next ranking update.
Sign up
Stay on top of the latest developments in the ecommerce industry. Sign up for a complimentary subscription to Digital Commerce 360 Retail News. Follow us on LinkedIn, Twitter and Facebook. Be the first to know when Digital Commerce 360 publishes news content.
Favorite